drugset / Trial / NCT05518695
Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese Subjects
RandomizedFactorialQuadruple-blindTreatment
Summary
To evaluate the safety and tolerability of BAT2022 in healthy subjects.
Timeline
- Start
- 2022-06-09
- Primary completion
- 2022-11-07
- Completion
- 2022-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT2022 | Unknown | 100 mg | Intravenous |
| Subject | BAT2022 | Unknown | 300 mg | Intravenous |
| Subject | BAT2022 | Unknown | 1000 mg | Intravenous |
| Subject | BAT2022 | Unknown | 1500 mg | Intravenous |